Development of prophylactic vaccines for genital and neonatal herpes

Authors: Jones, Cheryl A; Cunningham, Anthony L

Source: Expert Review of Vaccines, Volume 2, Number 4, August 2003 , pp. 541-549(9)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Over five decades numerous conventional candidate live attenuated and killed vaccines have failed to prevent genital herpes in clinical trials. However, a vaccine consisting of recombinant glycoprotein D from herpes simplex virus (HSV)-2 and deacylated monophosphoryl lipid A adjuvant has recently shown partial efficacy against clinical disease transmitted from HSV-1 and -2 seronegative women (73-74%). Comparisons between the efficacy of this vaccine and previous failed candidates and their effects on the immune system should help guide development of better vaccines through selection of appropriate HSV proteins, adjuvants or cytokines and newer vaccine vectors, such as DNA vaccines, recombinant viral vaccines and specific HSV mutants.

Keywords: animal models; clinical trials; genital herpes vaccine; herpes simplex virus; prophylaxis

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14760584.2.4.541

Publication date: 2003-08-01

More about this publication?

Expert Review of Vaccines provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites